JP2023507848A5 - - Google Patents
Info
- Publication number
- JP2023507848A5 JP2023507848A5 JP2022538737A JP2022538737A JP2023507848A5 JP 2023507848 A5 JP2023507848 A5 JP 2023507848A5 JP 2022538737 A JP2022538737 A JP 2022538737A JP 2022538737 A JP2022538737 A JP 2022538737A JP 2023507848 A5 JP2023507848 A5 JP 2023507848A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition according
- lag
- cdr
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025154757A JP2026001028A (ja) | 2019-12-23 | 2025-09-18 | 癌の治療のための療法 |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962952878P | 2019-12-23 | 2019-12-23 | |
| US201962952859P | 2019-12-23 | 2019-12-23 | |
| US62/952,878 | 2019-12-23 | ||
| US62/952,859 | 2019-12-23 | ||
| US202063019857P | 2020-05-04 | 2020-05-04 | |
| US63/019,857 | 2020-05-04 | ||
| US202063021556P | 2020-05-07 | 2020-05-07 | |
| US63/021,556 | 2020-05-07 | ||
| US202063031453P | 2020-05-28 | 2020-05-28 | |
| US63/031,453 | 2020-05-28 | ||
| US202063123581P | 2020-12-10 | 2020-12-10 | |
| US63/123,581 | 2020-12-10 | ||
| PCT/US2020/065873 WO2021133653A1 (en) | 2019-12-23 | 2020-12-18 | Therapy for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025154757A Division JP2026001028A (ja) | 2019-12-23 | 2025-09-18 | 癌の治療のための療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023507848A JP2023507848A (ja) | 2023-02-27 |
| JP2023507848A5 true JP2023507848A5 (cg-RX-API-DMAC7.html) | 2023-12-21 |
Family
ID=76575359
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022538737A Pending JP2023507848A (ja) | 2019-12-23 | 2020-12-18 | 癌の治療のための療法 |
| JP2025154757A Pending JP2026001028A (ja) | 2019-12-23 | 2025-09-18 | 癌の治療のための療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025154757A Pending JP2026001028A (ja) | 2019-12-23 | 2025-09-18 | 癌の治療のための療法 |
Country Status (13)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7745556B2 (ja) * | 2020-02-21 | 2025-09-29 | マクロジェニクス,インコーポレーテッド | Cd137結合分子及びその使用 |
| CA3196496A1 (en) * | 2020-10-23 | 2022-04-28 | Laurence David TOMS | Lag-3 antagonist therapy for lung cancer |
| KR20240028452A (ko) * | 2021-07-02 | 2024-03-05 | 제넨테크, 인크. | 암을 치료하기 위한 방법 및 조성물 |
| KR20240038005A (ko) * | 2021-07-16 | 2024-03-22 | 마크로제닉스, 인크. | B7-h3 항체의 약학적 조성물 및 그것의 용도 |
| IL309120A (en) * | 2021-07-28 | 2024-02-01 | Hoffmann La Roche | Methods and compositions for the treatment of cancer |
| EP4410835A4 (en) * | 2021-09-29 | 2025-09-24 | Akeso Biopharma Inc | ANTI-LAG3 ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE |
| TW202328198A (zh) * | 2021-10-21 | 2023-07-16 | 大陸商杭州阿諾生物醫藥科技有限公司 | 一種融合多肽及其用途 |
| US20240117051A1 (en) * | 2022-09-09 | 2024-04-11 | Akeso Biopharma, Inc. | Therapeutic combination and use thereof |
| TW202436339A (zh) * | 2023-01-31 | 2024-09-16 | 瑞士商赫孚孟拉羅股份公司 | 治療選自非小細胞肺癌或三陰性乳癌的癌症之用途 |
| WO2024163009A1 (en) * | 2023-01-31 | 2024-08-08 | Genentech, Inc. | Methods and compositions for treating urothelial bladder cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2542256T3 (da) * | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| RS64268B1 (sr) * | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
| TWI693232B (zh) * | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| TWI773646B (zh) * | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| PE20231958A1 (es) * | 2015-07-30 | 2023-12-06 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas |
| JP2018523686A (ja) * | 2015-08-17 | 2018-08-23 | マクロジェニクス,インコーポレーテッド | B7‐h3及びcd3に結合できる二重特異性1価ダイアボディ並びにその使用 |
| CN108367069B (zh) * | 2015-12-14 | 2022-08-23 | 宏观基因有限公司 | 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法 |
| CN109069633A (zh) * | 2016-04-15 | 2018-12-21 | 宏观基因有限公司 | 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法 |
| MX2018014950A (es) * | 2016-06-07 | 2019-04-25 | Macrogenics Inc | Terapia de combinacion. |
| JP7085709B2 (ja) * | 2016-06-20 | 2022-06-17 | エフ-スター セラピューティクス リミテッド | Pd-l1及びlag-3に結合する結合分子 |
| US20200148785A1 (en) * | 2017-03-29 | 2020-05-14 | Glycotope (GmbH) | Pd-l1 and ta-muc1 antibodies |
| CA3052532A1 (en) * | 2017-04-05 | 2018-10-11 | F. Hoffmann-La Roche Ag | Bispecific antibodies specifically binding to pd1 and lag3 |
| JP7301002B2 (ja) * | 2017-05-30 | 2023-06-30 | ブリストル-マイヤーズ スクイブ カンパニー | 抗lag-3抗体または抗lag-3抗体および抗pd-1もしくは抗pd-l1抗体を含む組成物 |
| WO2019148412A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
| US20210115138A1 (en) * | 2018-03-20 | 2021-04-22 | WuXi Biologics Ireland Limited | Novel bispecific pd-1/lag-3 antibody molecules |
-
2020
- 2020-12-18 KR KR1020227025578A patent/KR20220119694A/ko not_active Ceased
- 2020-12-18 AU AU2020412595A patent/AU2020412595A1/en active Pending
- 2020-12-18 CN CN202080090186.8A patent/CN114901306A/zh active Pending
- 2020-12-18 US US17/787,793 patent/US20230056230A1/en active Pending
- 2020-12-18 WO PCT/US2020/065873 patent/WO2021133653A1/en not_active Ceased
- 2020-12-18 BR BR112022012437A patent/BR112022012437A2/pt unknown
- 2020-12-18 MX MX2022007790A patent/MX2022007790A/es unknown
- 2020-12-18 IL IL294207A patent/IL294207A/en unknown
- 2020-12-18 CA CA3165839A patent/CA3165839A1/en active Pending
- 2020-12-18 EP EP20906153.0A patent/EP4081248A4/en active Pending
- 2020-12-18 JP JP2022538737A patent/JP2023507848A/ja active Pending
- 2020-12-22 TW TW109145572A patent/TW202138387A/zh unknown
-
2022
- 2022-06-17 ZA ZA2022/06743A patent/ZA202206743B/en unknown
-
2025
- 2025-09-18 JP JP2025154757A patent/JP2026001028A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Reichert et al. | The future of antibodies as cancer drugs | |
| JP6953612B2 (ja) | チェックポイントインヒビター二重特異性抗体 | |
| JP7720785B2 (ja) | 低pHで結合するために特異性が増強されたイピリムマブバリアント | |
| Shim | One target, different effects: a comparison of distinct therapeutic antibodies against the same targets | |
| JP2023519254A5 (cg-RX-API-DMAC7.html) | ||
| JP2020501531A5 (cg-RX-API-DMAC7.html) | ||
| JP2009541492A5 (cg-RX-API-DMAC7.html) | ||
| Hinoda et al. | Monoclonal antibodies as effective therapeutic agents for solid tumors | |
| JP2013529059A5 (cg-RX-API-DMAC7.html) | ||
| HRP20241289T1 (hr) | Molekule za vezanje pd-1 i postupci za njihovu uporabu | |
| JP2021525544A5 (cg-RX-API-DMAC7.html) | ||
| JP2021510736A5 (cg-RX-API-DMAC7.html) | ||
| CA2872226A1 (en) | Humanized pan-her antibody compositions | |
| CN114901306A (zh) | 用于治疗癌症的疗法 | |
| EP4588524A2 (en) | Anti-tigit and anti-pvrig in monotherapy and combination treatments | |
| JP2023536086A5 (cg-RX-API-DMAC7.html) | ||
| US20250215087A1 (en) | Combination therapy of kras inhibitor and treg depleting agent | |
| EP3929213A1 (en) | Anti-pd-l1 antibody and use thereof | |
| CN110997000A (zh) | 用于治疗ErbB-2/ErbB-3阳性肿瘤的抗体 | |
| MX2015000730A (es) | Tratamientos terapeuticos novedosos con anticuerpos anti-her2 que tienen una fucosilacion baja. | |
| JP2023548375A (ja) | Erbb3変異陽性がんを有する対象を治療するための手段及び方法 | |
| WO2021058735A1 (en) | Cancer treatment with anti-met antibody compositions | |
| KR20250130296A (ko) | 항-ccr8 항체 및 이의 용도 | |
| JP7726978B2 (ja) | 抗cldn-18.2抗体及びその用途 | |
| Zhu et al. | Next generation of antibody therapy for cancer |